---
layout: default
title: Docetaxel
description: "Docetaxel 的老藥新用潛力分析。最高證據等級 L1，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 61
evidence_level: L1
indication_count: 10
---

# Docetaxel

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L1</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Docetaxel：從HER2陽性乳癌到女性乳腺癌

## 一句話總結

<p class="key-answer" data-question="Docetaxel 可以用於治療什麼新適應症？">
Docetaxel 原本用於治療 HER2 陽性乳癌及轉移性胃癌。
TxGNN 模型預測它可能對**女性乳腺癌 (female breast carcinoma)** 有效，
目前有 **超過50個臨床試驗**和 **多篇文獻**支持這個方向。
</p>

## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | HER2陽性早期乳癌、轉移性乳癌、轉移性胃癌 |
| 預測新適應症 | 女性乳腺癌、Ewing sarcoma、well-differentiated fetal adenocarcinoma of the lung、small cell lung carcinoma、primary pulmonary lymphoma、botryoid-type embryonal rhabdomyosarcoma of the vagina、pulmonary blastoma、rhabdomyosarcoma (disease)、embryonal extrahepatic bile duct rhabdomyosarcoma、parameningeal embryonal rhabdomyosarcoma |
| TxGNN 預測分數 | 99.90% |
| 證據等級 | L1 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed |





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>Docetaxel 屬於 taxane 類抗腫瘤藥物，透過促進微管蛋白聚合並抑制微管解聚來干擾細胞分裂，</p>
<p>導致細胞週期停滯在 G2/M 期。其在乳癌治療中的療效已被廣泛證實，</p>
<p>包括與 trastuzumab、carboplatin 等藥物併用的多種治療方案。</p>
<p>預測其對女性乳腺癌有效具有明確的機轉基礎。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03879577" target="_blank">NCT03879577</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>53</td><td>Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women Wit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002707" target="_blank">NCT00002707</a></td><td>PHASE3</td><td>COMPLETED</td><td>2411</td><td>A RANDOMIZED TRIAL COMPARING PREOPERATIVE DOXORUBICIN (ADRIAMYCIN)/CYCLOPHOSPHAM...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01015963" target="_blank">NCT01015963</a></td><td>N/A</td><td>COMPLETED</td><td>69</td><td>A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00546364" target="_blank">NCT00546364</a></td><td>PHASE2</td><td>TERMINATED</td><td>62</td><td>IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01293851" target="_blank">NCT01293851</a></td><td>N/A</td><td>TERMINATED</td><td>3</td><td>Characterization of the Molecular-Genetic Mechanisms Associated With Chemotherap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00343512" target="_blank">NCT00343512</a></td><td>PHASE2</td><td>TERMINATED</td><td>34</td><td>Pilot Study of Neoadjuvant Dose Dense Docetaxel With Correlative Molecular Studi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00561119" target="_blank">NCT00561119</a></td><td>PHASE3</td><td>COMPLETED</td><td>326</td><td>Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05714553" target="_blank">NCT05714553</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>19</td><td>A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00014456" target="_blank">NCT00014456</a></td><td>PHASE1</td><td>COMPLETED</td><td>35</td><td>A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00963729" target="_blank">NCT00963729</a></td><td>PHASE3</td><td>COMPLETED</td><td>756</td><td>A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00193011" target="_blank">NCT00193011</a></td><td>PHASE3</td><td>COMPLETED</td><td>150</td><td>A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00047255" target="_blank">NCT00047255</a></td><td>PHASE3</td><td>COMPLETED</td><td>263</td><td>A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Tras...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04975451" target="_blank">NCT04975451</a></td><td>PHASE2</td><td>UNKNOWN</td><td>30</td><td>Neoadjuvant Treatment Anlotinib Combined With Docetaxel and Carboplatin in Tripl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003565" target="_blank">NCT00003565</a></td><td>PHASE2</td><td>COMPLETED</td><td>109</td><td>A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00104624" target="_blank">NCT00104624</a></td><td>PHASE2</td><td>TERMINATED</td><td>53</td><td>Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00678626" target="_blank">NCT00678626</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetax...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06234137" target="_blank">NCT06234137</a></td><td>NA</td><td>RECRUITING</td><td>154</td><td>A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carbop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02125019" target="_blank">NCT02125019</a></td><td>N/A</td><td>COMPLETED</td><td>62</td><td>Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cance...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03588091" target="_blank">NCT03588091</a></td><td>PHASE3</td><td>COMPLETED</td><td>355</td><td>A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02071862" target="_blank">NCT02071862</a></td><td>PHASE1</td><td>COMPLETED</td><td>210</td><td>Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00311636" target="_blank">NCT00311636</a></td><td>PHASE3</td><td>COMPLETED</td><td>280</td><td>Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00471432" target="_blank">NCT00471432</a></td><td>PHASE1</td><td>COMPLETED</td><td>40</td><td>A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00006104" target="_blank">NCT00006104</a></td><td>PHASE2</td><td>COMPLETED</td><td>46</td><td>A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin a...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00535509" target="_blank">NCT00535509</a></td><td>NA</td><td>COMPLETED</td><td>285</td><td>Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00539968" target="_blank">NCT00539968</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>5</td><td>An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00193115" target="_blank">NCT00193115</a></td><td>PHASE2</td><td>COMPLETED</td><td>32</td><td>Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05301010" target="_blank">NCT05301010</a></td><td>PHASE3</td><td>COMPLETED</td><td>128</td><td>Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01583426" target="_blank">NCT01583426</a></td><td>PHASE3</td><td>COMPLETED</td><td>1229</td><td>A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solven...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01094184" target="_blank">NCT01094184</a></td><td>PHASE4</td><td>COMPLETED</td><td>49</td><td>Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02897050" target="_blank">NCT02897050</a></td><td>PHASE2</td><td>SUSPENDED</td><td>170</td><td>Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed b...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00887536" target="_blank">NCT00887536</a></td><td>PHASE3</td><td>COMPLETED</td><td>1613</td><td>A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02225652" target="_blank">NCT02225652</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02624973" target="_blank">NCT02624973</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>200</td><td>PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00645866" target="_blank">NCT00645866</a></td><td>PHASE2</td><td>COMPLETED</td><td>47</td><td>A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01275677" target="_blank">NCT01275677</a></td><td>PHASE3</td><td>COMPLETED</td><td>3270</td><td>A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00258375" target="_blank">NCT00258375</a></td><td>PHASE2</td><td>COMPLETED</td><td>15</td><td>A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03170960" target="_blank">NCT03170960</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>914</td><td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02003209" target="_blank">NCT02003209</a></td><td>PHASE3</td><td>COMPLETED</td><td>315</td><td>A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Pa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00769470" target="_blank">NCT00769470</a></td><td>PHASE2</td><td>COMPLETED</td><td>18</td><td>A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00431080" target="_blank">NCT00431080</a></td><td>PHASE3</td><td>COMPLETED</td><td>478</td><td>A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequent...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05302336" target="_blank">NCT05302336</a></td><td>PHASE4</td><td>UNKNOWN</td><td>402</td><td>A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04931823" target="_blank">NCT04931823</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>126</td><td>A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability,...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00398489" target="_blank">NCT00398489</a></td><td>PHASE2</td><td>UNKNOWN</td><td>94</td><td>Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00039520" target="_blank">NCT00039520</a></td><td>PHASE2</td><td>COMPLETED</td><td>10</td><td>A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenoca...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02413320" target="_blank">NCT02413320</a></td><td>PHASE2</td><td>COMPLETED</td><td>101</td><td>Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00950300" target="_blank">NCT00950300</a></td><td>PHASE3</td><td>COMPLETED</td><td>596</td><td>A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Effica...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00665457" target="_blank">NCT00665457</a></td><td>PHASE2</td><td>TERMINATED</td><td>3</td><td>Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer Wit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00118053" target="_blank">NCT00118053</a></td><td>PHASE2</td><td>TERMINATED</td><td>5</td><td>A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03201861" target="_blank">NCT03201861</a></td><td>PHASE3</td><td>RECRUITING</td><td>762</td><td>Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Che...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01503905" target="_blank">NCT01503905</a></td><td>NA</td><td>UNKNOWN</td><td>600</td><td>Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Ass...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28398846/" target="_blank">28398846</a></td><td>2017</td><td>Article</td><td>Journal of clinical oncology :</td><td>Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7595719/" target="_blank">7595719</a></td><td>1995</td><td>Article</td><td>Journal of clinical oncology :</td><td>Docetaxel.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27997437/" target="_blank">27997437</a></td><td>2017</td><td>Article</td><td>Anti-cancer drugs</td><td>Association between adjuvant docetaxel-based chemotherapy and breast cancer-rela...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9282422/" target="_blank">9282422</a></td><td>1997</td><td>Article</td><td>Drug and therapeutics bulletin</td><td>Paclitaxel and docetaxel in breast and ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25073898/" target="_blank">25073898</a></td><td>2014</td><td>Article</td><td>World journal of surgical onco</td><td>Breast carcinoma with choriocarcinomatous features: a case report and review of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16020974/" target="_blank">16020974</a></td><td>2005</td><td>Article</td><td>Oncology</td><td>Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9364543/" target="_blank">9364543</a></td><td>1997</td><td>Article</td><td>Oncology (Williston Park, N.Y.</td><td>Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26874836/" target="_blank">26874836</a></td><td>2017</td><td>Article</td><td>Breast cancer (Tokyo, Japan)</td><td>Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37584416/" target="_blank">37584416</a></td><td>2023</td><td>Article</td><td>The Kaohsiung journal of medic</td><td>FTO-mediated epigenetic upregulation of LINC01559 confers cell resistance to doc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9252781/" target="_blank">9252781</a></td><td>1997</td><td>Article</td><td>Dermatology (Basel, Switzerlan</td><td>Docetaxel-induced subungual hemorrhage.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12714881/" target="_blank">12714881</a></td><td>2003</td><td>Article</td><td>American journal of clinical o</td><td>Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19755993/" target="_blank">19755993</a></td><td>2009</td><td>Article</td><td>British journal of cancer</td><td>Gene expression profile and response to trastuzumab-docetaxel-based treatment in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10791395/" target="_blank">10791395</a></td><td>2000</td><td>Article</td><td>Lancet (London, England)</td><td>The taxanes: an update.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23693018/" target="_blank">23693018</a></td><td>2013</td><td>Article</td><td>BMC cancer</td><td>Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24347519/" target="_blank">24347519</a></td><td>2014</td><td>Article</td><td>Annals of oncology : official </td><td>Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15074734/" target="_blank">15074734</a></td><td>2004</td><td>Article</td><td>Clinical oncology (Royal Colle</td><td>Trastuzumab and docetaxel for metastatic breast cancer: an experience from a can...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22105826/" target="_blank">22105826</a></td><td>2012</td><td>Article</td><td>Journal of clinical oncology :</td><td>Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early bre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36736488/" target="_blank">36736488</a></td><td>2023</td><td>Article</td><td>Chemico-biological interaction</td><td>The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-indu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28661759/" target="_blank">28661759</a></td><td>2017</td><td>Article</td><td>Journal of clinical oncology :</td><td>Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15858439/" target="_blank">15858439</a></td><td>2005</td><td>Article</td><td>Breast cancer (Tokyo, Japan)</td><td>Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluor...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Ewing sarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（13 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00014456" target="_blank">NCT00014456</a></td><td>PHASE1</td><td>COMPLETED</td><td>35</td><td>A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04183062" target="_blank">NCT04183062</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06669013" target="_blank">NCT06669013</a></td><td>PHASE3</td><td>RECRUITING</td><td>40</td><td>A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02511132" target="_blank">NCT02511132</a></td><td>PHASE2</td><td>COMPLETED</td><td>22</td><td>A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing&#x27;s Sa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00049296" target="_blank">NCT00049296</a></td><td>PHASE1</td><td>COMPLETED</td><td>26</td><td>Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00073983" target="_blank">NCT00073983</a></td><td>PHASE2</td><td>COMPLETED</td><td>54</td><td>Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01696669" target="_blank">NCT01696669</a></td><td>PHASE2</td><td>COMPLETED</td><td>43</td><td>Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensiv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05116800" target="_blank">NCT05116800</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03491371" target="_blank">NCT03491371</a></td><td>NA</td><td>COMPLETED</td><td>56</td><td>The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-trea...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03449901" target="_blank">NCT03449901</a></td><td>PHASE2</td><td>COMPLETED</td><td>98</td><td>A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05999994" target="_blank">NCT05999994</a></td><td>PHASE2</td><td>RECRUITING</td><td>105</td><td>CAMPFIRE: Children&#x27;s and Young Adult Master Protocol for Innovative Pediatric Re...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05634369" target="_blank">NCT05634369</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>50</td><td>A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002825" target="_blank">NCT00002825</a></td><td>PHASE2</td><td>COMPLETED</td><td>20</td><td>A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURREN...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28787430/" target="_blank">28787430</a></td><td>2017</td><td>Article</td><td>British journal of cancer</td><td>GEIS-21: a multicentric phase II study of intensive chemotherapy including gemci...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25164234/" target="_blank">25164234</a></td><td>2014</td><td>Article</td><td>BMC cancer</td><td>A study of docetaxel and irinotecan in children and young adults with recurrent ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35023660/" target="_blank">35023660</a></td><td>2021</td><td>Article</td><td>The Turkish journal of pediatr</td><td>Primary spinal multifocal intradural-extramedullary Ewing sarcoma in children: p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32386107/" target="_blank">32386107</a></td><td>2020</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28221727/" target="_blank">28221727</a></td><td>2017</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36890471/" target="_blank">36890471</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22302783/" target="_blank">22302783</a></td><td>2012</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18484657/" target="_blank">18484657</a></td><td>2008</td><td>Article</td><td>Cancer</td><td>Combination of gemcitabine and docetaxel in the treatment of children and young ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22363068/" target="_blank">22363068</a></td><td>2012</td><td>Article</td><td>The oncologist</td><td>Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15117993/" target="_blank">15117993</a></td><td>2004</td><td>Article</td><td>Journal of clinical oncology :</td><td>Laboratory and clinical evidence of synergistic cytotoxicity of sequential treat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29262551/" target="_blank">29262551</a></td><td>2017</td><td>Article</td><td>Oncotarget</td><td>The combination of temozolomide-irinotecan regresses a doxorubicin-resistant pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19727011/" target="_blank">19727011</a></td><td>2009</td><td>Article</td><td>Journal of pediatric hematolog</td><td>Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetax...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34496122/" target="_blank">34496122</a></td><td>2021</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on coope...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34974029/" target="_blank">34974029</a></td><td>2022</td><td>Article</td><td>Journal of controlled release </td><td>SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41488266/" target="_blank">41488266</a></td><td>2025</td><td>Article</td><td>Cureus</td><td>Recurrent Ewing&#x27;s Sarcoma of the Chest Wall in an Adolescent Male Patient: A Com...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20132000/" target="_blank">20132000</a></td><td>2010</td><td>Article</td><td>Expert review of anticancer th</td><td>Role of chemotherapy in the management of soft tissue sarcomas.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21795832/" target="_blank">21795832</a></td><td>2011</td><td>Article</td><td>Hinyokika kiyo. Acta urologica</td><td>[Retroperitoneal extraskeletal Ewing&#x27;ｓ sarcoma difficult to differentiate from a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39055564/" target="_blank">39055564</a></td><td>2024</td><td>Article</td><td>Frontiers in oncology</td><td>Case report: Metastatic refractory undifferentiated small round-cell sarcoma suc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26154614/" target="_blank">26154614</a></td><td>2015</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetax...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24753077/" target="_blank">24753077</a></td><td>2014</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. well-differentiated fetal adenocarcinoma of the lung</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23750171/" target="_blank">23750171</a></td><td>2013</td><td>Article</td><td>Tuberculosis and respiratory d</td><td>A case of locally advanced well-differentiated fetal adenocarcinoma of the lung ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00903292" target="_blank">NCT00903292</a></td><td>NA</td><td>UNKNOWN</td><td>52</td><td>Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03304093" target="_blank">NCT03304093</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00051974" target="_blank">NCT00051974</a></td><td>PHASE2</td><td>COMPLETED</td><td>155</td><td>A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01891123" target="_blank">NCT01891123</a></td><td>NA</td><td>UNKNOWN</td><td>300</td><td>An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04747470" target="_blank">NCT04747470</a></td><td>PHASE1</td><td>TERMINATED</td><td>13</td><td>A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacok...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02740985" target="_blank">NCT02740985</a></td><td>PHASE1</td><td>COMPLETED</td><td>313</td><td>A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmac...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00622349" target="_blank">NCT00622349</a></td><td>PHASE3</td><td>COMPLETED</td><td>707</td><td>A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01798485" target="_blank">NCT01798485</a></td><td>PHASE3</td><td>TERMINATED</td><td>696</td><td>A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00114192" target="_blank">NCT00114192</a></td><td>PHASE2</td><td>COMPLETED</td><td>37</td><td>Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01015963" target="_blank">NCT01015963</a></td><td>N/A</td><td>COMPLETED</td><td>69</td><td>A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00064636" target="_blank">NCT00064636</a></td><td>PHASE1</td><td>TERMINATED</td><td>46</td><td>A Phase I, Open Label, Dose Escalation Study of PS-341 Plus Docetaxel in Treatme...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00095225" target="_blank">NCT00095225</a></td><td>PHASE2</td><td>COMPLETED</td><td>122</td><td>A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02876081" target="_blank">NCT02876081</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06532032" target="_blank">NCT06532032</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>12</td><td>A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00862134" target="_blank">NCT00862134</a></td><td>PHASE2</td><td>TERMINATED</td><td>42</td><td>A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01138163" target="_blank">NCT01138163</a></td><td>PHASE2</td><td>COMPLETED</td><td>121</td><td>A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02766335" target="_blank">NCT02766335</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>116</td><td>A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squam...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02058433" target="_blank">NCT02058433</a></td><td>PHASE3</td><td>UNKNOWN</td><td>140</td><td>Phase 3, Randomized, Open-label Study of the Safety of Individual Paclitaxel Dos...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01348126" target="_blank">NCT01348126</a></td><td>PHASE2, PHASE3</td><td>TERMINATED</td><td>385</td><td>A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02959749" target="_blank">NCT02959749</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>147</td><td>Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00499109" target="_blank">NCT00499109</a></td><td>PHASE3</td><td>COMPLETED</td><td>275</td><td>Randomized Phase III Multicenter Trial of RRM1 &amp; ERCC1 Directed Customized Chemo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00686985" target="_blank">NCT00686985</a></td><td>PHASE2</td><td>COMPLETED</td><td>50</td><td>A Phase II Study of Docetaxel - Carboplatin As Second Line Treatment in Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02889666" target="_blank">NCT02889666</a></td><td>PHASE1</td><td>RECRUITING</td><td>500</td><td>A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06266299" target="_blank">NCT06266299</a></td><td>PHASE1</td><td>RECRUITING</td><td>101</td><td>A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00092001" target="_blank">NCT00092001</a></td><td>PHASE2</td><td>COMPLETED</td><td>111</td><td>A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01750281" target="_blank">NCT01750281</a></td><td>PHASE2</td><td>COMPLETED</td><td>212</td><td>A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Eff...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03976375" target="_blank">NCT03976375</a></td><td>PHASE3</td><td>COMPLETED</td><td>422</td><td>A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03735264" target="_blank">NCT03735264</a></td><td>PHASE2</td><td>UNKNOWN</td><td>46</td><td>Anlotinib Combined With Docetaxel For Advanced Non-Small Cell Lung Cancer After ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00741221" target="_blank">NCT00741221</a></td><td>PHASE2</td><td>COMPLETED</td><td>50</td><td>Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01802021" target="_blank">NCT01802021</a></td><td>PHASE2, PHASE3</td><td>UNKNOWN</td><td>120</td><td>Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06868732" target="_blank">NCT06868732</a></td><td>PHASE1</td><td>NOT_YET_RECRUITING</td><td>288</td><td>Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Ce...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01204099" target="_blank">NCT01204099</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>223</td><td>Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03358875" target="_blank">NCT03358875</a></td><td>PHASE3</td><td>COMPLETED</td><td>805</td><td>A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003900" target="_blank">NCT00003900</a></td><td>PHASE2</td><td>COMPLETED</td><td>48</td><td>A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients Wit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00020709" target="_blank">NCT00020709</a></td><td>PHASE3</td><td>COMPLETED</td><td>840</td><td>A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetax...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03407300" target="_blank">NCT03407300</a></td><td>PHASE2</td><td>UNKNOWN</td><td>80</td><td>A Prospective, Randomized Clinical Study of Safety and Efficacy by Using Docetax...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00536107" target="_blank">NCT00536107</a></td><td>PHASE4</td><td>TERMINATED</td><td>14</td><td>A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05089734" target="_blank">NCT05089734</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>603</td><td>Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govite...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02439346" target="_blank">NCT02439346</a></td><td>PHASE1</td><td>TERMINATED</td><td>15</td><td>An Open-label, Non-randomized, Multicenter Phase I Study to Characterize the Saf...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00026156" target="_blank">NCT00026156</a></td><td>PHASE2</td><td>COMPLETED</td><td>125</td><td>Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cel...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00118131" target="_blank">NCT00118131</a></td><td>PHASE2</td><td>TERMINATED</td><td>49</td><td>Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05714553" target="_blank">NCT05714553</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>19</td><td>A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03509584" target="_blank">NCT03509584</a></td><td>PHASE1</td><td>TERMINATED</td><td>6</td><td>Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00059943" target="_blank">NCT00059943</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02831491" target="_blank">NCT02831491</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00148291" target="_blank">NCT00148291</a></td><td>PHASE3</td><td>COMPLETED</td><td>180</td><td>Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced No...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04062708" target="_blank">NCT04062708</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>38</td><td>CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02780778" target="_blank">NCT02780778</a></td><td>PHASE2, PHASE3</td><td>UNKNOWN</td><td>20</td><td>Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00293085" target="_blank">NCT00293085</a></td><td>PHASE2</td><td>COMPLETED</td><td>37</td><td>An Open, Randomized, Multicentre, Phase II Pilot Study of Docetaxel and Cisplati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00014456" target="_blank">NCT00014456</a></td><td>PHASE1</td><td>COMPLETED</td><td>35</td><td>A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37196428/" target="_blank">37196428</a></td><td>2023</td><td>Article</td><td>Journal of clinical oncology :</td><td>Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36773042/" target="_blank">36773042</a></td><td>2023</td><td>Article</td><td>European journal of clinical p</td><td>Sequencing strategies with ramucirumab and docetaxel following prior treatments ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37945672/" target="_blank">37945672</a></td><td>2023</td><td>Article</td><td>Scientific reports</td><td>Detection of factors related to treatment reduction in docetaxel and ramucirumab...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20038723/" target="_blank">20038723</a></td><td>2010</td><td>Article</td><td>Journal of clinical oncology :</td><td>Molecular predictors of outcome with gefitinib and docetaxel in previously treat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39434017/" target="_blank">39434017</a></td><td>2024</td><td>Article</td><td>BMC cancer</td><td>Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advan...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32439358/" target="_blank">32439358</a></td><td>2020</td><td>Article</td><td>Cancer radiotherapie : journal</td><td>Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based che...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40404206/" target="_blank">40404206</a></td><td>2025</td><td>Article</td><td>Journal for immunotherapy of c</td><td>Development and validation of a serum proteomic test for predicting patient outc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34403911/" target="_blank">34403911</a></td><td>2021</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Randomized phase III study of docetaxel versus docetaxel plus intercalated erlot...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33982408/" target="_blank">33982408</a></td><td>2021</td><td>Article</td><td>Clinical and translational sci</td><td>Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31951770/" target="_blank">31951770</a></td><td>2020</td><td>Article</td><td>Journal of medical economics</td><td>Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatme...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30913364/" target="_blank">30913364</a></td><td>2019</td><td>Article</td><td>Thoracic cancer</td><td>Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31179803/" target="_blank">31179803</a></td><td>2019</td><td>Article</td><td>The Journal of international m</td><td>A phase II study of the combination of docetaxel and bevacizumab for previously ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30602615/" target="_blank">30602615</a></td><td>2019</td><td>Article</td><td>The oncologist</td><td>An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Ad...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40679002/" target="_blank">40679002</a></td><td>2025</td><td>Article</td><td>Pakistan journal of pharmaceut</td><td>Comparison of anlotinib combined with docetaxel versus single docetaxel as secon...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31631526/" target="_blank">31631526</a></td><td>2019</td><td>Article</td><td>Thoracic cancer</td><td>Retrospective cohort study on the safety and efficacy of docetaxel in Japanese n...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32464632/" target="_blank">32464632</a></td><td>2020</td><td>Article</td><td>Oncology</td><td>The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41373437/" target="_blank">41373437</a></td><td>2025</td><td>Article</td><td>International journal of molec</td><td>Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Prof...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32924677/" target="_blank">32924677</a></td><td>2020</td><td>Article</td><td>Journal of microencapsulation</td><td>Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-l...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27912835/" target="_blank">27912835</a></td><td>2017</td><td>Article</td><td>Hematology/oncology clinics of</td><td>Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34488513/" target="_blank">34488513</a></td><td>2021</td><td>Article</td><td>Expert review of clinical phar</td><td>Factors affecting the efficacy and safety of docetaxel combined with platinum in...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. primary pulmonary lymphoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（8 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03884556" target="_blank">NCT03884556</a></td><td>PHASE1</td><td>COMPLETED</td><td>56</td><td>Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05094336" target="_blank">NCT05094336</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>329</td><td>A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Phar...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06074588" target="_blank">NCT06074588</a></td><td>PHASE3</td><td>RECRUITING</td><td>556</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03611738" target="_blank">NCT03611738</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>21</td><td>Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCL...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00049296" target="_blank">NCT00049296</a></td><td>PHASE1</td><td>COMPLETED</td><td>26</td><td>Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04800146" target="_blank">NCT04800146</a></td><td>N/A</td><td>COMPLETED</td><td>177</td><td>A Prospective Observational Study on the Immune-response to SARS-CoV-2 Vaccinati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02604342" target="_blank">NCT02604342</a></td><td>PHASE3</td><td>COMPLETED</td><td>119</td><td>Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03786692" target="_blank">NCT03786692</a></td><td>PHASE2</td><td>RECRUITING</td><td>117</td><td>TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, Wit...</td></tr>
</tbody>
</table>

<h3>相關文獻（18 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23724913/" target="_blank">23724913</a></td><td>2013</td><td>Article</td><td>The New England journal of med</td><td>Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37593227/" target="_blank">37593227</a></td><td>2023</td><td>Article</td><td>EClinicalMedicine</td><td>AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19879424/" target="_blank">19879424</a></td><td>2009</td><td>Article</td><td>Advances in cancer research</td><td>Clusterin and chemoresistance.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32529467/" target="_blank">32529467</a></td><td>2020</td><td>Article</td><td>Investigational new drugs</td><td>A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homolo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31023244/" target="_blank">31023244</a></td><td>2019</td><td>Article</td><td>BMC cancer</td><td>Comparative survival benefit of currently licensed second or third line treatmen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36725772/" target="_blank">36725772</a></td><td>2023</td><td>Article</td><td>Thoracic cancer</td><td>Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19816079/" target="_blank">19816079</a></td><td>2009</td><td>Article</td><td>Onkologie</td><td>Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15812395/" target="_blank">15812395</a></td><td>2005</td><td>Article</td><td>Biology of blood and marrow tr</td><td>Phase I and pharmacokinetic study of docetaxel combined with melphalan and carbo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35042152/" target="_blank">35042152</a></td><td>2022</td><td>Article</td><td>ESMO open</td><td>Final efficacy and safety data, and exploratory molecular profiling from the pha...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30061946/" target="_blank">30061946</a></td><td>2018</td><td>Article</td><td>Oncology letters</td><td>CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29668860/" target="_blank">29668860</a></td><td>2018</td><td>Article</td><td>Annals of oncology : official </td><td>Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinas...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26446239/" target="_blank">26446239</a></td><td>2015</td><td>Article</td><td>The oncologist</td><td>U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatmen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24327273/" target="_blank">24327273</a></td><td>2014</td><td>Article</td><td>Clinical cancer research : an </td><td>Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28602779/" target="_blank">28602779</a></td><td>2017</td><td>Article</td><td>The Lancet. Oncology</td><td>Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lun...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32160733/" target="_blank">32160733</a></td><td>2020</td><td>Article</td><td>Hinyokika kiyo. Acta urologica</td><td>[A Case of Primary Central Nervous System Lymphoma that Developed during the Tre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41360030/" target="_blank">41360030</a></td><td>2026</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy v...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25170012/" target="_blank">25170012</a></td><td>2014</td><td>Article</td><td>The oncologist</td><td>FDA approval summary: crizotinib for the treatment of metastatic non-small cell ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32676310/" target="_blank">32676310</a></td><td>2020</td><td>Article</td><td>Translational lung cancer rese</td><td>Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. botryoid-type embryonal rhabdomyosarcoma of the vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pulmonary blastoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（3 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38835107/" target="_blank">38835107</a></td><td>2024</td><td>Article</td><td>The Journal of international m</td><td>Pulmonary blastoma with a good prognosis: a case report and review of the litera...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41626175/" target="_blank">41626175</a></td><td>2025</td><td>Article</td><td>Frontiers in oncology</td><td>Exceptional long-term survival in an adult with advanced classic biphasic pulmon...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23750171/" target="_blank">23750171</a></td><td>2013</td><td>Article</td><td>Tuberculosis and respiratory d</td><td>A case of locally advanced well-differentiated fetal adenocarcinoma of the lung ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. rhabdomyosarcoma (disease)</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.79%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（6 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04906876" target="_blank">NCT04906876</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06669013" target="_blank">NCT06669013</a></td><td>PHASE3</td><td>RECRUITING</td><td>40</td><td>A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05116800" target="_blank">NCT05116800</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03524898" target="_blank">NCT03524898</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>39</td><td>NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05634369" target="_blank">NCT05634369</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>50</td><td>A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002825" target="_blank">NCT00002825</a></td><td>PHASE2</td><td>COMPLETED</td><td>20</td><td>A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURREN...</td></tr>
</tbody>
</table>

<h3>相關文獻（9 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22302783/" target="_blank">22302783</a></td><td>2012</td><td>Article</td><td>Pediatric blood &amp; cancer</td><td>Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37422615/" target="_blank">37422615</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>A phase II study of gemcitabine and docetaxel combination in relapsed metastatic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36119541/" target="_blank">36119541</a></td><td>2022</td><td>Article</td><td>Frontiers in oncology</td><td>Embryonic esophageal rhabdomyosarcoma in an adult male: A case report and litera...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35529801/" target="_blank">35529801</a></td><td>2022</td><td>Article</td><td>Journal of kidney cancer and V</td><td>Primary Rhabdomyosarcoma of Kidney with Local Recurrence and Liver Metastasis in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36890471/" target="_blank">36890471</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20132000/" target="_blank">20132000</a></td><td>2010</td><td>Article</td><td>Expert review of anticancer th</td><td>Role of chemotherapy in the management of soft tissue sarcomas.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14585225/" target="_blank">14585225</a></td><td>2003</td><td>Article</td><td>Current treatment options in o</td><td>New therapeutic strategies for soft tissue sarcomas.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40755557/" target="_blank">40755557</a></td><td>2025</td><td>Article</td><td>Acta medica Philippina</td><td>Vulvar Rhabdomyosarcoma in an Adult Female Patient: A Case Report and Review of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16532433/" target="_blank">16532433</a></td><td>2006</td><td>Article</td><td>Cancer</td><td>Phase II investigation of docetaxel in pediatric patients with recurrent solid t...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. embryonal extrahepatic bile duct rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. parameningeal embryonal rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 多張許可證 | 曲斯若凍晶注射劑150毫克 | 注射劑 | HER2陽性早期乳癌輔助治療、轉移性乳癌、轉移性胃癌 |

## 細胞毒性

| 項目 | 內容 |
|------|------|
| 細胞毒性分類 | 傳統細胞毒性藥物 (Taxane類) |
| 骨髓抑制風險 | 高度 (嗜中性白血球減少為主要毒性) |
| 致吐性分級 | 低度 |
| 監測項目 | CBC（含分類）、肝功能、周邊神經病變 |
| 處置防護 | 需依細胞毒性藥物處置規範操作 |

## 安全性考量

- **主要不良反應**：嗜中性白血球減少、過敏反應、周邊神經病變、液體滯留
- **預防措施**：需預先給予 dexamethasone 以減少液體滯留和過敏反應




### 藥物-食物交互作用 (DFI)

<div class="dfi-source">資料來源：<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>（原文內容請參閱該網站）</div>

**葡萄柚汁** 🟢 Minor
- 影響：影響藥物代謝。可能增加藥物血中濃度。
- 建議：避免大量攝取。需監測療效或不良反應。避免食用葡萄柚或葡萄柚汁。

### 藥物-草藥交互作用 (DHI)

**聖約翰草（貫葉連翹）** 🔴 Major
- 影響：聖約翰草降低化療藥物療效
- 建議：化療期間禁用所有草藥補充品


### 藥物-疾病注意事項 (DDSI)

<div class="ddsi-source">資料來源：<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>（原文內容請參閱該網站）</div>

**Alcoholism** 🟡 Moderate
- 需定期監測。

**Paresthesia** 🟡 Moderate
- 可能有嚴重不良反應。出現症狀時應考慮停藥。

**Infections** 🟢 Minor
- 本藥物在此情況下禁用。需定期監測。風險包括：骨髓抑制、感染。

**Edema** 🟢 Minor
- 可能有嚴重不良反應。

**Eye Diseases** 🟢 Minor
- 必要時應停止治療。

**肝臟疾病** 🟢 Minor
- 不應使用本藥物。可能有致命風險。

**Bone Marrow Failure Disorders** 🟢 Minor
- 本藥物在此情況下禁用。風險包括：骨髓抑制、感染、血栓、貧血。可能有嚴重不良反應。

## 結論與下一步

**決策：Proceed**

**理由：**
Docetaxel 在女性乳腺癌的臨床應用已有大量 Phase 3 試驗支持，療效證據充分，
且作用機轉與預測適應症高度相關。

**若要推進需要：**
- 針對特定乳癌亞型的精準治療方案優化
- 減少周邊神經病變等長期毒性的策略研究

---

## 相關藥物報告

- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - 證據等級 L1
- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - 證據等級 L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - 證據等級 L1
- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - 證據等級 L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - 證據等級 L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Docetaxel老藥新用驗證報告. https://twtxgnn.yao.care/drugs/docetaxel/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_docetaxel,
  title = {Docetaxel老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/docetaxel/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
